INNOCARE (09969) saw its shares increase by nearly 3%. At the time of writing, the stock was up 2.67%, trading at HK$14.24 with a turnover of HK$29.20 million. The movement follows an announcement from the company on April 27, via its official social media channels, that multiple research findings related to its self-developed novel BCL2 inhibitor Mesutoclax (ICP-248) and novel BTK inhibitor orelabrutinib have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Notably, the study on Mesutoclax for the treatment of myeloid malignancies was chosen for an oral presentation, while research on Mesutoclax for B-cell malignancies was selected for a poster presentation.